Impact of Skipping an Antibiotic Dose in H. pylori Therapy

Why Adherence is Critical

The American Gastroenterological Association (AGA) explicitly identifies inadequate adherence as one of the usual causes of refractory H. pylori infection, and poor compliance directly reduces eradication rates, with studies using medication monitoring systems demonstrating that taking less than 85% of prescribed antibiotics leads to substantially lower cure rates 1, 2, 3

Missing doses creates gaps in antibiotic coverage, allowing H. pylori to survive and potentially develop resistance, with subtherapeutic drug levels and low trough levels being critical factors, particularly for amoxicillin, which requires at least 2g daily divided into 3-4 doses to maintain adequate trough levels 1, 2, 6, 7
Incomplete antibiotic exposure provides selective pressure for resistant strains to emerge, with resistance development being a significant concern 4, 5

Treatment failure from poor adherence doubles antibiotic exposure unnecessarily, as failed therapy requires retreatment with different regimens, creating a cascade of problems, including the need for more complex second-line regimens and susceptibility testing after two treatment failures with confirmed adherence 1, 4, 5, 6, 8
Patients who fail first-line therapy require more complex second-line regimens, and after two treatment failures with confirmed adherence, susceptibility testing becomes necessary 1, 3, 6

Providers must emphasize completing the full therapeutic course before initiating treatment, with specific strategies including explaining dosing complexity, addressing barriers proactively, clarifying expected adverse events, and stressing the rationale for complete treatment 1, 3, 6, 7
Longer treatment durations provide higher eradication rates, making adherence throughout the entire course even more critical, with 14-day treatment durations achieving higher cure rates than 7-day durations 1, 5, 6, 7, 8

Assuming partial treatment is better than none is false, as incomplete therapy promotes resistance without achieving eradication, and underestimating compliance issues can lead to treatment failure, with studies showing that more than 10% of patients are poor compliers, taking less than 85% of prescribed doses 2, 4, 5, 8